Biotech · Private company · Gainesville, FL, US

Cyclo Therapeutics, Inc.

SEC CIK 0000922247

Track this companyFree. Adds Cyclo Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials40 recruiting or active

Pipeline programs3From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline3

Hydroxypropyl-beta-cyclodextrinPhase 3 · Niemann-Pick Disease, Type C1ClinicalTrials.gov · fetched Nov 12, 2026
Hydroxypropyl Beta CyclodextrinPhase 2 · Alzheimer's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Hydroxypropyl-β-cyclodextrinPhase 1 · Niemann-Pick Disease, Type C1ClinicalTrials.gov · fetched Nov 12, 2026

A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's DiseasePHASE2 · UNKNOWN · started Sep 23, 2022ClinicalTrials.gov NCT05607615 · fetched Nov 12, 2026
Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1PHASE3 · UNKNOWN · started Jul 20, 2021ClinicalTrials.gov NCT04860960 · fetched Nov 12, 2026
Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol Cyclo (HPβCD) in Niemann-Pick Disease Type CPHASE1 · UNKNOWN · started May 23, 2019ClinicalTrials.gov NCT03893071 · fetched Nov 12, 2026
Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)PHASE1 · COMPLETED · started Oct 11, 2017ClinicalTrials.gov NCT02939547 · fetched Nov 12, 2026